CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (15,390,749)	$ (11,154,849)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense	283,637	260,646
Amortization of intangible asset	1,764,382	1,626,476
Amortization of deferred license, royalty and subscription revenues	(220,764)	(186,035)
Amortization of deferred grant income	(261,777)	(261,777)
Amortization of deferred consulting fees	582,186	582,186
Amortization of deferred license and royalty fees	82,129	82,125
Amortization of deferred rent	(8,143)	32,403
Stock-based compensation	986,769	828,395
Options issued as independent director compensation	454,366	427,516
Reduction in receivables from the reversal of revenues	205,926	0
Write-off of security deposit	(3,634)	0
Write off of expired inventory	0	1,510
Loss on sale/write-off of fixed assets	4,997	6,502
Net loss allocable to noncontrolling interest	(2,763,169)	(1,833,943)
Changes in operating assets and liabilities:
Accounts receivable, net	(459,555)	(25,272)
Grant receivable	584,744	256,714
Inventory	(5,794)	21,154
Prepaid expenses and other current assets	140,220	(320,893)
Accounts payable and accrued liabilities	(699,155)	(331,072)
Other long term liabilities	(16,686)	(31,741)
Deferred grant income	56,630	271,655
Net cash used in operating activities	(14,683,440)	(9,748,300)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(205,135)	(780,524)
Payment of license fee	0	(1,500)
Cash paid, net of cash acquired for assets	0	(246,850)
Cash acquired in connection with merger	292,387	5,908
Proceeds from the sale of fixed assets	4,500	0
Security deposit (paid)/received	(529)	250
Net cash provided by/(used) in investing activities	91,223	(1,022,716)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of stock options from employees	286,552	106,153
Proceeds from the exercise of stock options from directors	0	112,328
Proceeds from the exercise of stock options from outside consultant	0	4,700
Proceeds from the exercise of warrants	0	425,000
Proceeds from the sale of common shares of subsidiary	0	3,213,500
Net cash provided by financing activities	286,552	3,861,681
Effect of exchange rate changes on cash and cash equivalents	(75,885)	(185,291)
NET CHANGE IN CASH AND CASH EQUIVALENTS:	(14,381,550)	(7,094,626)
Cash and cash equivalents at beginning of period	22,211,897	33,324,924
Cash and cash equivalents at end of period	7,830,347	26,230,298
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	315	1,073
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Common shares acquired in connection with investment in subsidiary as part of Share Exchange and Contribution Agreement	2,001,762	0
Common shares issued in connection with investment in subsidiary	0	6,000,000
Common shares issued in connection with the purchase of assets	0	2,300,000
Common shares issued as part of merger	1,802,684	2,600,000
Warrants issued as part of merger	$ 0	$ 954,879